(±)-Lisofylline

CHF 56.00
In stock
CDX-H0117-M01010 mgCHF 56.00
CDX-H0117-M05050 mgCHF 186.00
 
More Information
Product Details
Synonyms 1-(5'-Hydroxyhexyl)-3,7-dimethylxanthine; LSF; BL 194; CT-1501R; 5-Hydroxy pentoxifylline
Product Type Chemical
Properties
Formula C13H20N4O3
MW 280.3
CAS 6493-06-7
Source/Host Chemicals Synthetic.
Purity Chemicals ≥99% (HPLC)
Appearance White powder.
Solubility Soluble in chloroform.
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key NSMXQKNUPPXBRG-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Synthetic methylxanthine metabolite of pentoxifylline. Potent anti-inflammatory agent in which only the (−) optical isomer is biologically active. Inhibits the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase (LPAAT), which has been shown to protect mice from endotoxic shock. Decreases lipid peroxidation in vitro and in vivo. Suppresses the production of the proinflammatory cytokine IFN-γ, inhibits IL-12-mediated STAT-4 activation, enhances glucose-stimulated β-cell insulin secretion, reducing the onset of diabetes in a non-obese diabetic mouse model, and blocks autoimmune deterioration of pancreatic β cells in non-obese diabetic mice. Compound can be used as analytical reference material.
Product References
(1) G.C. Rice, et al.; PNAS 91, 3857 (1994) | (2) E. Clarke, et al.; Cancer Res. 56, 105 (1996) | (3) N. Hasegawa, et al.; Am. J. Respir. Crit. Care Med. 155, 928 (1997) | (4) S. Itani, et al.; Metabolism 50, 553 (2001) | (5) S. Itani, et al.; Diabetes 51, 2005 (2002) | (6) M. Chen, et al.; Endocrinol. 143, 2341 (2002) | (7) Z. Yang, et al.; Ann. N.Y. Acad. Sci. 1005, 409 (2003) | (8) J.S. Striffler, et al;.Metab. Clin. Exp. 53, 290 (2004) | (9) Z. Yang, et al.; Biochem. Pharmacol. 69, 1 (2005) | (10) E. Wyska; Pharmacology 85, 264 (2010)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.